




Institute of  
Medicinal Plants

## Journal of Medicinal Plants

Journal homepage: [www.jmp.ir](http://www.jmp.ir)



### Research Article

## The effect of a standardized polyherbal formulation for endometriosis-associated pain: A randomized double-blind placebo-controlled clinical trial

Elham Akhtari<sup>1,2</sup>, Fataneh Hashem-Dabaghian<sup>1,2</sup>, Amirhossein Jamshidi<sup>1,3</sup>, Akram Fallah<sup>1,2,4</sup>, Majid Dadmehr<sup>1,2,\*</sup>

<sup>1</sup> Institute for Studies in Medical History, Persian and Complementary Medicine, Iran University of Medical Sciences, Tehran, Iran

<sup>2</sup> Department of Traditional Medicine, School of Persian Medicine, Iran University of Medical Sciences, Tehran, Iran

<sup>3</sup> Department of Traditional Pharmacy, School of Persian Medicine, Iran University of Medical Sciences, Tehran, Iran

<sup>4</sup> Student Research Committee, Iran University of Medical Sciences, Tehran, Iran

### ARTICLE INFO

#### Keywords:

Endometriosis  
Pelvic pain  
Herbal medicine  
Quality of life

### ABSTRACT

**Background:** Dysmenorrhea, dyspareunia and endometriosis-associated pain are considered the main complications in young women with endometriosis. Proscur capsule contains several traditional herbal medicines that have shown anti-inflammatory, antioxidant, anti-androgenic, anti-estrogenic, pelvic pain reducing and analgesic effects in previous pre-clinical and clinical studies. **Objective:** This study aimed to investigate the clinical efficacy and safety of a standardized polyherbal formulation (proscur) for endometriosis-associated pain in young women with endometriosis. **Methods:** This study was a single-center, randomized, double-blinded, placebo-controlled, clinical trial. A total of 90 patients aged 20–45 years with endometriosis-associated pain were enrolled. Participants were randomly assigned to the proscur or placebo groups in a ratio of 1:1 and efficacy evaluation was conducted at day 30, 60 and 90. The participants orally administered proscur or placebo two times a day for 12 weeks. The study outcomes were measured based on a change of visual analogue scale (VAS) score and the short form endometriosis health profile questionnaire (EHP-5). **Results:** We observed an increase in pain relief in women who receive proscur. The serum measures of CA-125 declined in those who received proscur. Intervention was well tolerated, and no serious adverse events occurred. **Conclusions:** Our study showed that proscur relieved endometriosis-associated pain and CA-125 level with minimal side-effects after treatment. Therefore, proscur combined with standard medical therapy could provide more clinical benefits for patients with endometriosis-associated pain.

**Abbreviations:** OCs, oral contraceptives; GnRH, gonadotropin-releasing hormone; NSAIDs, non-steroidal anti-inflammatory drugs; CAM, complementary and alternative medicine; CONSORT, Consolidated Standards of Reporting Trials; VAS, visual analogue scale; EHP-5, endometriosis health profile questionnaire; SD, standard deviation; TNF- $\alpha$ , tumor necrosis factor alpha; VEGF, vascular endothelial growth factor; IL-6, interleukin-6

\*Corresponding author: [majiddadmehr@yahoo.com](mailto:majiddadmehr@yahoo.com), [dadmehr.m@iums.ac.ir](mailto:dadmehr.m@iums.ac.ir)

doi: [10.61186/jmp.23.91.75](https://doi.org/10.61186/jmp.23.91.75)

Received 16 October 2024; Received in revised form 26 November 2024; Accepted 23 December 2024

© 2023. Open access. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<https://creativecommons.org/licenses/by-nc/4.0/>)

## 1. Introduction

Endometriosis is a chronic and inflammatory gynecological disease characterized by the abnormal presence of endometrial epithelium and stroma outside the uterine cavity [1]. It causes multiple clinical manifestations, including chronic pelvic pain, dysmenorrhea, dyspareunia, nausea, dyschezia, dysuria, fatigue and infertility [1-3]. Among them, endometriosis-associated pain is one of the principal manifestations of endometriosis, which includes dysmenorrhea, dyspareunia, and non-menstrual chronic pelvic pain [4]. More than 170 million women worldwide and up to 10% of reproductive-age women are affected by endometriosis [5]. To diagnose endometriosis, measuring blood biomarker levels such as CA-125 and CA19-9 (important predictors for patients with endometriosis), and imaging methods such as transvaginal ultrasound and MRI are common non-invasive method [6, 7]. Furthermore, visual inspection at laparoscopy and histological confirmation of endometriosis are considered the gold standard tests for definitive diagnosis of disease [8]. Current treatment options include laparoscopic removal of lesions and medical therapies, including hormonal treatments that suppress ovarian hormone production and also pain relief agents [2, 9]. Pharmacological therapy is the first line of treatment, which focusing on the use of oral contraceptives (OCs), gonadotropin-releasing hormone (GnRH) agonists, non-steroidal anti-inflammatory drugs (NSAIDs) and other analgesics [10, 11]. However, medical treatments are often not prescribed long-term due to lack of success, high cost and various side effects, including abnormal uterine bleeding, headache, mood changes, loss of bone marrow density, hot flashes, gastric ulcers, cardiovascular events, and acute kidney injury

[2, 12]. Although, laparoscopic ablation or excision of all visible lesions is beneficial in reducing pain and other endometriosis-related symptoms [13], surgery is probably related with peri- and postoperative complications, and the possibility of endometriosis recurrence is high [5, 14]. Nevertheless, endometriosis-associated pain can even continue after medical and/or surgical treatments [15]. Moreover, pain exposes patients to psychological comorbidities such as anxiety and depression and reduced quality of life, including a deterioration of sleep quality and lower activity levels [15, 16]. Given the limitations of standard treatments, there is growing interest in complementary and alternative (CAM) therapies for the management of endometriosis, including adjustment in diet [17], herbal medicines [14, 18], one of the CAM methods [19, 20], and acupuncture intervention [21]. Herbal medicines have a long history of use for various gynecological disorders, including endometriosis [3]. Several preclinical and clinical studies have confirmed the effectiveness of some medicinal plants and their secondary metabolites on endometriosis that they can be used for symptom relief [14].

Plant-based bioactive compounds such as phenolic compounds (flavonoids and phenolic acids) and some other plant-derived secondary metabolites are effective in endometriosis through different molecular mechanisms of action, including anti-inflammatory, anti-oxidant, anti-proliferative, apoptotic, antiangiogenesis, anti-invasive, immunomodulatory, and estrogen modulating activities [14, 17, 18]. Proscur capsule, a standardized pharmaceutical preparation, containing *Serenoa repens* (W.Bartram) Small (saw palmetto), *Zingiber officinale* Roscoe (ginger), *Camellia sinensis* (L.) Kuntze (green

tea), *Urtica dioica* L. (nettle), *Rosmarinus officinalis* L. (rosemary) and *Cucurbita muschata* L. (pumpkin). Saw palmetto has anti-androgenic, anti-estrogenic, anti-inflammatory, and antioxidant properties [22]. Several studies have reported ginger, green tea, and rosemary have pelvic pain reducing properties and can reduce dysmenorrhea [23-25]. Furthermore, preclinical studies have shown that nettle, green tea, rosemary, and ginger can reduce the size of endometriosis lesions [26-29]. However, adequate data is not available on the clinical efficacy and safety of proscur for endometriosis-associated pain. Thus, the present study aimed to evaluate the efficacy and safety of proscur capsule on endometriosis-associated pelvic pain in young Iranian women compared to placebo.

## 2. Materials and Methods

### 2.1. Study design

This study was a randomized, double-blind, placebo controlled, clinical trial conducted from December 21, 2021 to June 20, 2022, in a tertiary care center. The study protocol was reviewed and approved by the Medical Ethics Committee of Iran University of Medical Sciences [Ethics committee reference number: IR.IUMS.REC.1400.783] and registered in the Iranian Registry of Clinical Trials [IRCT registration number: IRCT20211201053241N1]. The objectives and details of the study were clearly explained to all the included patients and they signed a written informed consent form before participation. For designing and reporting this trial the Consolidated Standards of Reporting Trials (CONSORT) has been used as frameworks of methodology.

### 2.2. Participants

The study population was mainly enrolled from women with pelvic pain associated with

minimal/mild endometriosis. Patients who met these criteria were enrolled in this trial: (1) women aged 20 to 45 years; (2) definitive diagnosis of endometriosis; and (3) moderate to severe endometriosis-associated pain ( $4 \leq \text{VAS} \leq 10$ ). Participants with any of the following criteria excluded from the study: (1) Pregnancy intention within three months; (2) breast feeding; (3) need for endometriosis surgery; and (4) unwillingness to take herbal medicine. Moreover, the main withdrawal criteria were as follows: (1) Usage of any hormonal agents and/or other alternative and complementary medications that might interact with the intervention during the study; (2) medication compliance less than 80 %; (3) occurrence of pregnancy; and (4) intolerable adverse events.

### 2.3. Randomization and blinding

The subjects who met the eligibility criteria randomly were divided into two groups using a random form. Randomization was done by block method and in a 1:1 constant allocation ratio using the "Random allocation software". The random list was prepared by a statistician, then sealed envelopes were used for allocation concealment. The type of intervention (A/B) was written inside sealed envelopes and the number of patients was written on the envelope. The envelopes were given to the person doing the sampling. Therefore, the patients and the person who is evaluated the symptoms and outcomes were blinded of the type of intervention.

### 2.4. Interventions

The patients in intervention group ( $n = 45$ ) received one proscur capsule twice a day every morning and night with plenty of water for 12 weeks. The control group ( $n = 45$ ) received placebo capsule based on the same regimen and

duration (two times a day for 12 weeks). Both groups were allowed to use oral mefenamic acid (MFA) 250 mg capsule if they could not tolerate the pain during the study period. The number of MFA capsules consumed on average in the last month was recorded at the beginning of the study and on the 30th, 60th and 90th days of the study. Demographic characteristics, including age, marital status, occupation, menarche onset, endometriosis onset, level of CA-125, intensity of period pain, dyspareunia, and pelvic pain, and amount of painkiller consumption to control pain were recorded at the beginning of the study.

### 2.5. Preparation of the proscur and the placebo capsules

Proscur capsule was the product of Goldaru Herbal Pharmaceutical Company, Isfahan, IRAN. Each capsule contains *Serenoa repens* (W.Bartram) Small (saw palmetto) extract with *Zingiber officinale* Roscoe (ginger) extract, *Camellia sinensis* (L.) Kuntze (green tea), *Urtica dioica* L., *Rosmarinus officinalis* L. (rosemary) and *Cucurbita muschata* L. (pumpkin) seed oil. (The ingredients of each proscur capsule are as follows: saw palmetto: 160 mg, green tea: 50 mg, pumpkin seed oil: 48 mg, ginger: 40 mg, stinging nettle (ethanolic extract): 25 mg, stinging nettle (aqueous extract): 25 mg, rosemary: 5 mg and selenium 25 mcg). The proscur and placebo capsules were identical in shape, size, color, taste, and smell (placebo capsules contained starch). Both of them were prepared in the same place. Participants consecutively received treatment packages.

### 2.6. Sample size calculation

The sample size was calculated using two-mean comparison formula. When an  $\alpha$  value of 0.05 with power 80 % and a 20 % dropout rate were considered and the effect size of 0.65 was

assumed for dysmenorrhea, the sample size of each group was determined to be 45.

### 2.7. Study outcomes

The principal objective of this study was to determine the effect of proscur capsule on dysmenorrhea in patients with endometriosis. Pain intensity was measured using visual analogue scale (VAS) at the beginning of the study and on the 30th, 60th and 90th days of the study. The VAS is one of the most common, feasible, valid and reliable scales to measure the intensity or frequency of pain. It is a line that starts from zero and ends with the number 10, the amount of pain that a patient feels ranges across a continuum from none (0) to an extreme amount (10) of pain [30-32].

The short form endometriosis health profile questionnaire (EHP-5) was used to investigate the effect of endometriosis on the quality of life of the study participants. The EHP-5 consists of two parts. The first part contains 5 questions about the effect of endometriosis on walking, mood, self-image and social support and the second part contains 6 questions about the effect of endometriosis on doing personal work, child care, sexual intimacy, concern about infertility. Both parts include never, rarely, sometimes, often, and always answers that assess the severity of the problem in the previous 4 weeks (5 items, ranges 0-4). The patient must answer the 5 questions in the first part and the questions related to her condition (regarding marriage and having children) in the second part. Finally, the total score of 5 questions of the first part (core questionnaire) and 6 questions of the second part (modular questionnaire) is prepared a total score (range 0-100, from best to worst possible health status). This questionnaire was designed by Jones et al. [33-35] and its Persian version was validated by Goshtasebi et al. [36]. At the

end of each month, the intensity of pain and the amount of painkiller consumption were recorded, and at the end of the third month, the EHP-5 questionnaire was completed again.

### 2.8. Adherence/patient safety

To check medication compliance, patients were asked to mark the medication consumption in a sheet at each appointment and provide it to the project manager at the end of each month to assess how the patient took each of her medications. Patients were asked to hand over all their empty medication cans. During the study, all patients were observed weekly for any adverse events.

### 2.9. Statistical analysis

Data were analyzed using the Statistical Package for the Social Sciences software (version 23, BM Corp., Armonk, N.Y., USA). Mean and standard deviation were used to describe quantitative data, and frequency percentage was used to describe qualitative data. After assessing the distribution of quantitative variables by Kolmogorov-Smirnov test, the Mann-Whitney U test was used to compare the intensity of pain and the amount of pain reduction between two groups. The qualitative data were compared with Chi-square or Fisher-exact test (where assumptions of Chi-square test did not exist) between groups. The changes in the pain intensity in each group during the study was evaluated with the Friedman test (a non-parametric equivalent for repeated measures ANOVA). P value was considered 0.05 to compare the percentage of pain reduction between two groups.

## 3. Results

Among a total of 145 patients with endometriosis-associated pain were investigated

for eligibility, 90 patients were included in the study and 45 people were randomly assigned to each group. In the intervention group, three patients were excluded from the study due to heart burn and in the placebo group, two patients were excluded because of abdominal pain. Finally, 85 patients completed the study and were included in the analysis (43 patients in proscur group and 42 patients in the placebo group). A CONSORT flow diagram of the study is presented in Figure 1. Baseline demographic properties and general characteristics of the patients are demonstrated in Table 1.

The severity of dysmenorrhea, pelvic pain, dyspareunia and painkiller consumption in two groups at different times of the study are shown in Table 2.

At the end of the study, the percentage of reduction in the severity of dysmenorrhea, dyspareunia, pelvic pain and painkiller consumption in the intervention group was more than the placebo group. The amount of painkiller consumption showed a significant decrease in the intervention group after 3 months, while there was no significant change in the control group.

During the study, the level of CA-125 in the proscur group changed from  $151.16 \pm 79.7$  to  $52.6 \pm 35.52$  ( $P < 0.001$ ) and in the control group, it went from  $109 \pm 47.35$  to  $97.31 \pm 42.64$  ( $P < 0.001$ ). Although the amount of this antigen showed a significant decrease in both groups after 3 months, the percentage of decrease was  $62.56 \pm 17.3$  % in the proscur group and  $6.7 \pm 7.69$  % in the control group. However, the CA-125 in the proscur group decreased significantly more than the control group ( $P < 0.001$ ).

The results of the EHP-5 questionnaire before and after the intervention in two groups are shown in Table 3.

There is a significant difference between the two groups in terms of the EHP-5 scores after the intervention. In the intervention group, 11 people complained of the capsule being stuck in the esophagus and a burning sensation that got better with eating, and 4 people complained of stomachache. Abdominal pain was also reported in 2 patients in the placebo group.




Fig. 1. The CONSORT flow diagram of the study

**Table 1.** Basement characteristics of the participants

|                                      | Proscur (n = 43) | Placebo (n = 42) | p value |
|--------------------------------------|------------------|------------------|---------|
| Age (year)                           | 32.69 ± 7.68     | 31.78 ± 7.72     | 0.587   |
| Marital status                       | Single           | 22 (51.2 %)      | 1       |
|                                      | Married          | 20 (48.8 %)      |         |
| Age of menarche (year)               | 12.22 ± 0.86     | 11.97 ± 0.81     | 0.24    |
| Age at onset of endometriosis (year) | 21.4 ± 3.17      | 21.5 ± 3.54      | 0.989   |

Note: Values are presented as mean ± SD or percent.  
Abbreviations: SD, standard deviation.

**Table 2.** Primary and secondary outcomes before and after interventions in each group

|                                    | Group   | Baseline    | 30th day    | 60th day    | 90th day    | P value <sup>a</sup> | Changes from baseline to 90th day | P value <sup>b</sup> |
|------------------------------------|---------|-------------|-------------|-------------|-------------|----------------------|-----------------------------------|----------------------|
| Severity of dysmenorrhea           | Proscur | 7.09 ± 1.1  | 4.45 ± 1.44 | 2.72 ± 0.98 | 1.5 ± 0.59  | < 0.001              | 78.77 ± 8.12                      | < 0.001              |
|                                    | Placebo | 6.56 ± 0.7  | 6.02 ± 0.74 | 6.17 ± 0.71 | 6.24 ± 0.61 | 0.014                | 2.51 ± 8.15                       |                      |
| Severity of dyspareunia            | Proscur | 5.92 ± 1.89 | 3.13 ± 1.57 | 2 ± 1.04    | 1.43 ± 0.72 | < 0.001              | 78.84 ± 9.67                      | < 0.001              |
|                                    | Placebo | 6.56 ± 0.72 | 6.05 ± 0.53 | 5.88 ± 0.96 | 6.05 ± 0.53 | 0.096                | 4.44 ± 11.6                       |                      |
| Severity of pelvic pain            | Proscur | 6.73 ± 1.12 | 4.02 ± 1.27 | 2.27 ± 0.81 | 1.45 ± 0.59 | < 0.001              | 78.13 ± 9.31                      | < 0.001              |
|                                    | Placebo | 6.47 ± 0.7  | 6.14 ± 0.73 | 6.12 ± 0.73 | 6.15 ± 0.5  | 0.021                | 3.3 ± 8.49                        |                      |
| Amount of painkiller used (number) | Proscur | 4.24 ± 1.34 | 2.48 ± 0.89 | 1.81 ± 0.62 | 1.37 ± 0.56 | < 0.001              | 65.6 ± 18.05                      | < 0.001              |
|                                    | Placebo | 4.7 ± 0.99  | 4.34 ± 0.88 | 4.47 ± 0.94 | 4.52 ± 0.99 | 0.209                | -0.14 ± 8.19                      |                      |

Note: Values presented as mean ± SD or percent.  
Abbreviations: SD, standard deviation.

<sup>a</sup> Friedman test

<sup>b</sup> Mann–Whitney U test was used to compare the mean difference of variables between the two groups (non-normally distributed).

**Table3.** EHP-5 scores before and after interventions in each group

|                                      | Group   | Baseline      | p value* | 90th day after intervention | p value* |
|--------------------------------------|---------|---------------|----------|-----------------------------|----------|
| Score of EHP-5 core questionnaire    | Proscur | 52.31 ± 11.57 | 0.57     | 27.75 ± 15.52               | < 0.001  |
|                                      | Placebo | 52.37 ± 8.62  |          | 50 ± 6.62                   |          |
| Score of EHP-5 modular questionnaire | Proscur | 47.07 ± 18.53 | 1        | 24.5 ± 16.86                | < 0.001  |
|                                      | Placebo | 45.12 ± 12.53 |          | 44.24 ± 12.06               |          |
| EHP-5 total score                    | Proscur | 99.39 ± 26.2  | 0.837    | 52.25 ± 31.13               | < 0.001  |
|                                      | Placebo | 97.5 ± 15.93  |          | 93.93 ± 14.67               |          |

Note: Values are presented as mean ± SD or percent.  
Abbreviations: EHP-5, endometriosis health profile questionnaire.

\*Mann Whitney U test

#### 4. Discussion

As far as we know, the present study is the first clinical trial that evaluated the effects of proscur capsule on the endometriosis-associated pelvic pain in young women. The findings of our study demonstrated that consumption of formula proscur consisting of saw palmetto, green tea, pumpkin seed oil, ginger, nettle and, rosemary could significantly relieve endometriosis-associated pain and CA-125 level, when used for 12 weeks. The pathogenesis of endometriosis is not precisely known [17], however, the interaction between hormonal, immune, inflammatory and proangiogenic processes are involved in the development of endometriosis [37]. Although clinical trials are lacking, there are preclinical studies showing the potential effectiveness of the bioactive compounds in proscur in the management of endometriosis through various molecular mechanisms, including anti-inflammatory, antioxidant, anti-androgenic, anti-estrogenic, and pelvic pain-reducing activities. Saw palmetto extract has anti-androgenic, anti-estrogenic, anti-inflammatory and prolactin inhibiting effects [22, 38]. Green tea has shown anti-inflammatory, antioxidant and pain-relieving properties [39-41]. Moreover, it has anti-angiogenic, anti-proliferation, anti-metastasis, and apoptosis induction properties. Administration of green tea has been shown to inhibit the growth of endometriosis in preclinical study [27]. In a study on the experimental mouse model of endometriosis, treatment with green tea catechin displayed anti-angiogenic effects and was able to significantly prevent the development of endometriosis [42]. Major bioactive component of green tea called epigallocatechin-3-gallate (EGCG) has anti-angiogenic and anti-oxidation activity, which can reduce the size and weight

of endometriosis lesions. Moreover, it was able to prevent the growth of lesions by increasing apoptosis and inhibiting the function of microvessels in experimental endometriosis lesions [43]. A cross-sectional study found that green tea consumption was associated with a lower prevalence of dysmenorrhea in women of reproductive age. Furthermore, green tea consumption was more significant in reducing moderate to severe dysmenorrhea than mild dysmenorrhea. However, the exact amount and duration of green tea consumption were not stated in this study [24]. According to currently available evidence, nettle-derived phytochemicals have been shown to possess anti-inflammatory, antioxidant and immunomodulatory activities [44]. Treatment with nettle in the rat model of endometriosis was able to significantly reduce the size of the lesion and the number of adhesions. Also, the levels of angiogenesis mediators (tumor necrosis factor alpha (TNF- $\alpha$ ), vascular endothelial growth factor (VEGF), and interleukin-6 (IL-6)) decreased due to the presence of flavonoids in this plant [45]. Phytocompounds in rosemary, responsible for anti-inflammatory, antioxidant, antiproliferative, and antitumor activities [46]. Administration of carnosic acid and rosmarinic acid of rosemary could significantly reduce the size of endometriosis lesions in mice compared to the control group. Both compounds were able to considerably suppress cell proliferation [28].

A comparison of rosemary and MFA capsules on menstrual bleeding and primary dysmenorrhea in a clinical trial on 82 female students with moderate dysmenorrhea showed rosemary has pain relief properties and can reduce dysmenorrhea the same as MFA capsules [25]. Pumpkin have anti-inflammatory and antioxidant activities. Pumpkin seeds

contain a notable amount of omega 3 [47]. Omega-3 treatment in a rat model was able to significantly reduce the size and tissue parameters of experimentally induced endometriotic implants [48]. The results of a meta-analysis showed that omega-3 consumption is effective in reducing the severity of dysmenorrhea [49]. Ginger root has anti-inflammatory and antispasmodic activities and is used for dysmenorrhea caused by endometriosis [17]. The application of ginger extract in a rat model caused reduction and atrophy of the endometriotic implants [29]. A crossover clinical trial study of 168 single female students with menstrual pain reported that the use of ginger for two consecutive cycles was as effective as a painkiller (Novafen) in relieving dysmenorrhea [23]. According to the findings of a systematic review of clinical trials, ginger was effective in treating primary dysmenorrhea, and its use was as effective as NSAIDs without any side effects [50]. This study has several limitations. Due to the limited evidence available on the clinical outcome of any of the plant alone in similar conditions, it was not possible to compare the findings obtained in the present study with other clinical studies. Furthermore, to assess the long-term effects of the intervention, patients had no follow-up after the study ended.

## 5. Conclusion

The results of the present study provide evidence of the efficacy of the proscur mixture

## References

1. Gao Q, Shen L, Jiang B, Luan Y-f, Lin L-n, Meng F-c, Wang C-y and Cong H-f. *Salvia miltiorrhiza*-containing Chinese herbal medicine combined with GnRH Agonist for postoperative treatment of endometriosis: A systematic review

(saw palmetto, green tea, pumpkin seed oil, ginger, nettle, and rosemary) as a supplement in the management of patients with endometriosis. The findings of this study show that short-term use of proscur capsule and conventional medicine can improve pelvic pain in patients with endometriosis. In addition, this product declined the serum measures of CA-125. More randomized controlled trials with larger sample sizes and longer follow-up periods are still necessary to confirm the findings of the present study.

## Author contributions

EA: Project administration, conceptualization and visualization. FHD: Methodology, statistical analysis, review and editing original draft. AHJ: Supervision, review and editing original draft. AF: Provision of study materials/patients and carried out experiments. MD: Writing, review and editing original draft. All authors read and approved the final version of the manuscript.

## Conflicts of interest

The authors do not have any conflict of interest to declare.

## Acknowledgment

This study was funded by Iran University of Medical Sciences (IUMS), Tehran, Iran; (Grant no. 19441).

and meta-analysis. *Frontiers in Pharmacology*. 2022; 13. doi: 10.3389/fphar.2022.831850.

2. DiVasta AD, Stamoulis C, Gallagher JS, Laufer MR, Anchan R and Hornstein MD. Nonhormonal therapy for endometriosis: a randomized, placebo-controlled, pilot study of


- cabergoline versus norethindrone acetate. *F&S Rep.* 2021; 2(4): 454-461. doi: 10.1016/j.xfre.2021.07.003.
3. Hartmann G and McEwen BJ. 'The potential of herbal medicine' in the management of endometriosis. *Journal of the Australian Traditional-Medicine Society.* 2018; 24(3): 146-154.
  4. Bourdel N, Alves J, Pickering G, Ramilo I, Roman H and Canis M. Systematic review of endometriosis pain assessment: how to choose a scale? *Hum Reprod Update* 2015; 21(1): 136-152. doi: 10.1093/humupd/dmu046.
  5. Della Corte L, Di Filippo C, Gabrielli O, Reppuccia S, La Rosa VL, Ragusa R, Fichera M, Commodari E, Bifulco G and Giampaolino P. The burden of Endometriosis on women's lifespan: A narrative overview on quality of life and psychosocial wellbeing. *Int. J. Environ. Res. and Public Health.* 2020; 17(13): 4683. doi: 10.3390/ijerph17134683.
  6. Nisenblat V, Bossuyt PMM, Shaikh R, Farquhar C, Jordan V, Scheffers CS, Mol BWJ, Johnson N and Hull ML. Blood biomarkers for the non-invasive diagnosis of endometriosis. *Cochrane Database of Syst. Rev.* 2016; 2016(5): CD012179. doi: 10.1002/14651858.cd012179.
  7. Ahn SH, Singh V and Tayade C. Biomarkers in endometriosis: challenges and opportunities. *Fertil. Steril.* 2017; 107(3): 523-532. doi: 10.1016/j.fertnstert.2017.01.009.
  8. Nisenblat V, Bossuyt PMM, Farquhar C, Johnson N and Hull ML. Imaging modalities for the non-invasive diagnosis of endometriosis. *Cochrane Database Syst. Rev.* 2016; 2(2): CD009591. doi: 10.1002/14651858.CD009591.pub2.
  9. Saunders PTK and Horne AW. Endometriosis: Etiology, pathobiology, and therapeutic prospects. *Cell.* 2021; 184(11): 2807-2824. doi: 10.1016/j.cell.2021.04.041.
  10. Johnson NP, Hummelshoj L, Abrao MS, Adamson GD, Allaire C, Amelung V, Andersson E, Becker C, Birna Árdal KB, Bush D, de Bie B, Chwalisz K, Critchley H, D'Hooghe T, Dunselman G, Evers JLH, Farquhar C, Faustmann T, Forman A, Fourquet J, Fraser I, Giudice L, Gordts S, Guidone H, Guo SW, Healy D, Hedon B, Hulkkonen J, Hull L, Hummelshoj L, Johnson NP, Just M, Kiesel L, Lam A, Lynam C, Mettler L, Miller C, North H, Pai R, Petta C, Prentice L, Reilly S, Reis F, Rolla E, Rombauts L, Schweppe KW, Seckin T, Sharpe-Timms K, Shepperson Mills D, Singh S, Soriano D, Stafford-Bell M, Stratton P, Taylor R, Tsaltas J, Veit J and Vercellini P. Consensus on current management of endometriosis. *Hum. Reprod.* 2013; 28(6): 1552-1568. doi: 10.1093/humrep/det050.
  11. Taylor HS, Giudice LC, Lessey BA, Abrao MS, Kotarski J, Archer DF, Diamond MP, Surrey E, Johnson NP, Watts NB, Gallagher JC, Simon JA, Carr BR, Dmowski WP, Leyland N, Rowan JP, Duan WR, Ng J, Schwefel B, Thomas JW, Jain RI and Chwalisz K. Treatment of Endometriosis-associated pain with Elagolix, an oral GnRH Antagonist. *New England Journal of Medicine.* 2017; 377(1): 28-40. doi: 10.1056/NEJMoa1700089.
  12. Chen LH, Lo WC, Huang HY and Wu HM. A lifelong impact on Endometriosis: Pathophysiology and pharmacological treatment. *Int. J. Mol. Sci.* 2023; 24(8). 7503. doi: 10.3390/ijms24087503.
  13. Bafort C, Beebejaun Y, Tomassetti C, Bosteels J and Duffy JMN. Laparoscopic surgery for endometriosis. *Cochrane Database of Systematic Reviews.* 2020; 2020(10). doi: 10.1002/14651858.CD011031.pub3.
  14. Meresman GF, Götte M and Laschke MW. Plants as source of new therapies for endometriosis: a review of preclinical and

- clinical studies. *Hum. Reprod. Update.* 2021; 27(2): 367-392. doi: 10.1093/humupd/dmaa039.
15. Muharam R, Amalia T, Pratama G, Harzif AK, Agiananda F, Maidarti M, Azyati M, Sumapraja K, Winarto H, Wiweko B, Hestiantoro A, Suarthana E and Tulandi T. Chronic pelvic pain in women with Endometriosis is associated with psychiatric disorder and quality of life deterioration. *Inter. J. Women's Health.* 2022; 14: 131-138. doi: 10.2147/ijwh.s345186.
16. Szyplowska M, Tarkowski R and Kułak K. The impact of endometriosis on depressive and anxiety symptoms and quality of life: a systematic review. *Front. Public Health.* 2023; 11. doi: 10.3389/fpubh.2023.1230303.
17. Ilhan M, Gurağaç Dereli FT and Akkol EK. Novel drug targets with traditional herbal medicines for overcoming endometriosis. *Curr. Drug Deliv.* 2019; 16(5): 386-399. doi: 10.2174/1567201816666181227112421.
18. Bina F, Soleymani S, Toliat T, Hajimahmoodi M, Tabarrai M, Abdollahi M and Rahimi R. Plant-derived medicines for treatment of endometriosis: A comprehensive review of molecular mechanisms. *Pharmacol. Res.* 2019; 139: 76-90. doi: 10.1016/j.phrs.2018.11.008.
19. Adamietz A, Boosz A, Mueller A, Hornung D, Trunk K, Beckmann MW, Dittrich R and Hack CC. Complementary and alternative medicine (CAM) in women with endometriosis. *Eur. J. Obstet. Gynecol. Reprod. Biol.* 2021; 262: 7-12. doi: 10.1016/j.ejogrb.2021.05.002.
20. Kong S, Zhang Y-H, Liu C-F, Tsui I, Guo Y, Ai B-B and Han F-J. The complementary and alternative medicine for Endometriosis: A review of utilization and mechanism. *Evid. Based Complement. Alternat. Med.* 2014; 2014: 146383. doi: 10.1155/2014/146383.
21. Li PS, Peng XM, Niu XX, Xu L, Hung Yu Ng E, Wang CC, Dai JF, Lu J and Liang RN. Efficacy of acupuncture for endometriosis-associated pain: a multicenter randomized single-blind placebo-controlled trial. *Fertil. Steril.* 2023; 119(5): 815-823. doi: 10.1016/j.fertnstert.2023.01.034.
22. Yang J and Te AE. Saw palmetto and finasteride in the treatment of category III prostatitis/chronic pelvic pain syndrome. *Curr. Urol. Rep.* 2005; 6(4): 290-5. doi: 10.1007/s11934-005-0026-1.
23. Adib Rad H, Basirat Z, Bakouei F, Moghadamnia AA, Khafri S, Farhadi Kotenaei Z, Nikpour M and Kazemi S. Effect of Ginger and Novafen on menstrual pain: A cross-over trial. *Taiwan J. Obstet Gynecol.* 2018; 57(6): 806-809. doi: 10.1016/j.tjog.2018.10.006.
24. Zhang X, Zhang R, Chen D, Huang R, Tian Y, Zhang P and Zhang J. Association of tea drinking and dysmenorrhoea among reproductive-age women in Shanghai, China (2013-2015): A cross-sectional study. *BMJ Open.* 2019; 9(4): e026643. doi: 10.1136/bmjopen-2018-026643.
25. Tahoonian-Golkhatmy F, Abedian Z, Emami SA and Esmaily H. Comparison of Rosemary and Mefenamic Acid capsules on menstrual bleeding and primary dysmenorrhea: A clinical trial. *Iran. J. Nurs. Midwifery Res.* 2019; 24(4): 301-305. doi: 10.4103/ijnmr.IJNMR\_99\_18.
26. Ilhan M, Ali Z, Khan IA, Taştan H and Akkol EK. Bioactivity-guided isolation of flavonoids from *Urtica dioica* L. and their effect on endometriosis rat model. *J. Ethnopharmacol.* 2019; 243: 112100. doi: 10.1016/j.jep.2019.112100.
27. Chen X, Man GCW, Hung SW, Zhang T, Fung LWY, Cheung CW, Chung JPW, Li TC and Wang CC. Therapeutic effects of green tea

- on endometriosis. *Crit. Rev. Food Sci. Nutr.* 2023; 63(18): 3222-3235. doi: 10.1080/10408398.2021.1986465.
28. Ferella L, Bastón JI, Bilotas MA, Singla JJ, González AM, Olivares CN and Meresman GF. Active compounds present in *Rosmarinus officinalis* leaves and *Scutellaria baicalensis* root evaluated as new therapeutic agents for endometriosis. *Reprod Biomed Online.* 2018; 37(6): 769-782. doi: 10.1016/j.rbmo.2018.09.018.
29. Filho JMdM, Neto JN, Gomes LMRdS, Ramos ISF, Oliveira SSR, Melo GCF, Silva LA, Moura ECR and Leal PdC. *Zingiber officinale* Roscoe (Ginger) as a complementary option for clinical treatment of Endometriosis: An experimental study in rats. *J. Med Food.* 2021; 24(4): 342-347. doi: 10.1089/jmf.2019.0320.
30. Modarresi S, Lukacs MJ, Ghodrati M, Salim S, MacDermid JC and Walton DM. A systematic review and synthesis of psychometric properties of the numeric pain rating scale and the visual analog scale for use in people with neck pain. *Clin. J. Pain.* 2021; 38(2): 132-148. doi: 10.1097/ajp.0000000000000999.
31. Begum MR and Hossain MA. Validity and reliability of visual analogue scale (VAS) for pain measurement. *J. Med. Case Rep. Rev.* 2019; 2(11): 394-402.
32. Aicher B, Peil H, Peil B and Diener H. Pain measurement: Visual analogue scale (VAS) and verbal rating scale (VRS) in clinical trials with OTC analgesics in headache. *Cephalalgia.* 2012; 32(3): 185-197. doi: 10.1177/03331024111430856.
33. Jones G, Jenkinson C and Kennedy S. Development of the short form endometriosis health profile questionnaire: the EHP-5. *Qual. Life Res.* 2004; 13(3): 695-704. doi: 10.1023/B:QURE.0000021321.48041.0e.
34. Selcuk S, Sahin S, Demirci O, Aksoy B, Eroglu M, Ay P and Cam C. Translation and validation of the Endometriosis Health Profile (EHP-5) in patients with laparoscopically diagnosed endometriosis. *European Journal of Obstetrics & Gynecology and Reproductive Biology.* 2015; 185: 41-44.
35. Jones GL, Budds K, Taylor F, Musson D, Raymer J, Churchman D, Kennedy SH and Jenkinson C. A systematic review to determine use of the Endometriosis Health Profiles to measure quality of life outcomes in women with endometriosis. *Human reproduction update.* 2024; 30 (2): 186-214.
36. Goshtasebi A, Nematollahzadeh M, Hariri FZ and Montazeri A. The short form endometriosis health profile (EHP-5): translation and validation study of the Iranian version. *Journal of ovarian research.* 2011; 4: 11. doi: 10.1186/1757-2215-4-11.
37. Zondervan KT, Becker CM and Missmer SA. Endometriosis. *The New England journal of medicine.* 2020; 382 (13): 1244-1256. doi: 10.1056/NEJMr1810764.
38. Kwon Y. Use of saw palmetto (*Serenoa repens*) extract for benign prostatic hyperplasia. *Food Sci Biotechnol.* 2019; 28 (6): 1599-1606. doi: 10.1007/s10068-019-00605-9.
39. Ohishi T, Goto S, Monira P, Isemura M and Nakamura Y. Anti-inflammatory Action of Green Tea. *Anti-inflammatory & anti-allergy agents in medicinal chemistry.* 2016; 15 (2): 74-90. doi: 10.2174/1871523015666160915154443.
40. Shahrahmani H and Kariman N. The effect of green tea ointment on episiotomy pain and wound healing in primiparous women: A randomized, double-blind, placebo-controlled clinical trial. 2018; 32 (3): 522-530. doi: 10.1002/ptr.5999.

41. Hashempur MH, Sadrneshin S, Mosavat SH and Ashraf A. Green tea (*Camellia sinensis*) for patients with knee osteoarthritis: A randomized open-label active-controlled clinical trial. *Clinical Nutrition (Edinburgh, Scotland)*. 2018; 37(1): 85-90. doi: 10.1016/j.clnu.2016.12.004.
42. Xu H, Lui WT, Chu CY, Ng PS, Wang CC and Rogers MS. Anti-angiogenic effects of green tea catechin on an experimental endometriosis mouse model. *Hum. Reproduction (Oxford, England)*. 2009; 24(3): 608-618. doi: 10.1093/humrep/den417.
43. Wang CC, Xu H, Man GC, Zhang T, Chu KO, Chu CY, Cheng JT, Li G, He YX, Qin L, Lau TS, Kwong J and Chan TH. Prodrug of green tea epigallocatechin-3-gallate (Pro-EGCG) as a potent anti-angiogenesis agent for endometriosis in mice. *Angiogenesis*. 2013; 16(1): 59-69. doi: 10.1007/s10456-012-9299-4.
44. Taheri Y, Quispe C, Herrera-Bravo J, Sharifi-Rad J, Ezzat ShM, Merghany RM, Shaheen Sh, Azmi L, Mishra AP, Sener B, Kılıç M, Sen S, Acharya K, Nasiri A, Cruz-Martins N, Fokou PVT, Ydyrys A, Bassygarayev Z, Daştan SD, Alshehri MM, Calina D and Cho WC. *Urtica dioica*-derived phytochemicals for pharmacological and therapeutic applications. 2022; 2022: 4024331. doi: 10.1155/2022/4024331.
45. İlhan M, Ali Z, Khan IA, Taştan H and Küpeli Akkol E. Bioactivity-guided isolation of flavonoids from *Urtica dioica* L. and their effect on endometriosis rat model. *J. Ethnopharmacol.* 2019; 243: 112100. doi: 10.1016/j.jep.2019.112100.
46. de Oliveira JR and Camargo SEA. *Rosmarinus officinalis* L. (rosemary) as therapeutic and prophylactic agent. 2019; 26(1): 5. doi: 10.1186/s12929-019-0499-8.
47. Rani R, Kumar S and Yadav S. Pumpkin and chia seed as dietary fibre source in meat products: A review. *Pharma Innov. J.* 2021; 10(1): 477-485.
48. Akyol A, Şimşek M, İlhan R, Can B, Baspınar M, Akyol H, Gül HF, Gürsu F, Kavak B and Akın M. Efficacies of vitamin D and omega-3 polyunsaturated fatty acids on experimental endometriosis. *Taiwan. J. Obstet. Gynecol.* 2016; 55(6): 835-839. doi: 10.1016/j.tjog.2015.06.018.
49. Mohammadi MM, Mirjalili R and Faraji A. The impact of omega-3 polyunsaturated fatty acids on primary dysmenorrhea: a systematic review and meta-analysis of randomized controlled trials. *Eur. J. Clin. Pharmacol.* 2022; 78(5): 721-731. doi: 10.1007/s00228-021-03263-1.
50. Negi R, Sharma SK, Gaur R, Bahadur A and Jelly P. Efficacy of Ginger in the treatment of primary dysmenorrhea: A systematic review and meta-analysis. *Cureus*. 2021; 13(3): e13743. doi: 10.7759/cureus.13743.

How to cite this article: Akhtari E, Hashem-Dabaghian F, Jamshidi AH, Fallah A, Dadmehr M. The effect of a standardized polyherbal formulation for endometriosis-associated pain: A randomized double-blind placebo-controlled clinical trial. *Journal of Medicinal Plants* 2024; 23(91): 75-87. doi: 10.61186/jmp.23.91.75



## اثر یک فرمول استاندارد شده چند گیاهی برای درد مرتبط با اندومتريوز: یک کارآزمایی بالینی تصادفی دوسوکور کنترل شده با دارونما

الهام اختری<sup>۱،۲</sup>، فثانه هاشم دباغیان<sup>۱،۲</sup>، امیرحسین جمشیدی<sup>۱،۳</sup>، اکرم فلاح<sup>۱،۲،۴</sup>، مجید دادمهر<sup>۱،۲\*</sup>

<sup>۱</sup> موسسه مطالعات تاریخ پزشکی، طب ایرانی و مکمل، دانشگاه علوم پزشکی ایران، تهران، ایران

<sup>۲</sup> گروه طب سنتی، دانشکده طب ایرانی، دانشگاه علوم پزشکی ایران، تهران، ایران

<sup>۳</sup> گروه داروسازی سنتی، دانشکده پزشکی ایرانی، دانشگاه علوم پزشکی ایران، تهران، ایران

<sup>۴</sup> کمیته تحقیقات دانشجویی، دانشگاه علوم پزشکی ایران، تهران، ایران

### چکیده

### اطلاعات مقاله

گل‌واژگان:

اندومتريوز

درد لگن

داروهای گیاهی

کیفیت زندگی

**مقدمه:** دیسمنوره، دیسپارونی و درد ناشی از آندومتريوز از عوارض اصلی در زنان جوان مبتلا به آندومتريوز محسوب می‌شوند. کپسول پروسکور حاوی چندین داروی گیاهی سنتی است که در مطالعات پیش بالینی و بالینی اثرات ضد التهابی، آنتی‌اکسیدانی، ضد آندروژنی، ضد استروژنی، کاهش‌دهنده درد لگنی و ضد درد را نشان داده‌اند. **هدف:** این مطالعه با هدف بررسی کارایی بالینی و ایمنی یک فرمول استاندارد چند گیاهی (پروسکور) برای دردهای مرتبط با آندومتريوز در زنان جوان مبتلا به آندومتريوز انجام شد. **روش بررسی:** این مطالعه یک کارآزمایی بالینی تصادفی، دوسوکور، تک مرکزی و کنترل شده با دارونما بود. در مجموع ۹۰ بیمار ۲۰ تا ۴۵ ساله با درد مرتبط با آندومتريوز وارد مطالعه شدند. شرکت‌کنندگان به‌طور تصادفی به گروه‌های پروسکور یا دارونما به نسبت ۱:۱ تقسیم شدند و ارزیابی اثربخشی در روزهای ۳۰، ۶۰ و ۹۰ انجام شد. شرکت‌کنندگان به مدت ۱۲ هفته دو بار در روز پروسکور یا دارونما را به صورت خوراکی دریافت کردند. نتایج مطالعه بر اساس نمره تغییر مقیاس آنالوگ بصری (VAS) و فرم کوتاه پرسشنامه پروفایل سلامت آندومتريوز (EHP-5) اندازه‌گیری شد. **نتایج:** ما شاهد افزایش تسکین درد در زنانی بودیم که پروسکور دریافت کردند. اندازه سطوح سرمی CA-125 در کسانی که پروسکور دریافت کردند کاهش یافت. مداخله به خوبی تحمل شد و هیچ عارضه جانبی جدی رخ نداد. **نتیجه‌گیری:** مطالعه ما نشان داد که پروسکور درد ناشی از آندومتريوز و سطح CA-125 را با حداقل عوارض جانبی پس از درمان تسکین می‌دهد. بنابراین، پروسکور همراه با درمان دارویی استاندارد می‌تواند مزایای بالینی بیشتری را برای بیماران مبتلا به درد مرتبط با آندومتريوز فراهم کند.

**مخفف‌ها:** OCS، داروهای ضد بارداری خوراکی؛ GnRH، هورمون آزاد کننده گنادوتروپین؛ NSAID، داروهای ضد التهابی غیر استروئیدی؛ CAM، طب مکمل و جایگزین؛ CONSORT، استانداردهای تلفیقی گزارش کارآزمایی‌ها؛ VAS، مقیاس آنالوگ بصری؛ EHP-5، پرسشنامه مشخصات سلامت آندومتريوز؛ SD، انحراف استاندارد؛ TNF- $\alpha$ ، فاکتور نکروز تومور آلفا؛ VEGF، فاکتور رشد اندوتلیال عروقی؛ IL-6، اینترلوکین-۶

\* نویسنده مسؤول: [majiddadmehr@yahoo.com](mailto:majiddadmehr@yahoo.com)، [dadmehr.m@iums.ac.ir](mailto:dadmehr.m@iums.ac.ir)

تاریخ دریافت: ۲۵ مهر ۱۴۰۳؛ تاریخ دریافت اصلاحات: ۶ آذر ۱۴۰۳؛ تاریخ پذیرش: ۳ دی ۱۴۰۳

doi: [10.61186/jmp.23.91.75](https://doi.org/10.61186/jmp.23.91.75)

© 2023, Open access. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<https://creativecommons.org/licenses/by-nc/4.0/>)